## Highlights of This Issue 709

### THERAPEUTIC DISCOVERY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>711</td>
<td>hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications</td>
<td>Laure Deville, Josette Hillion, Frédéric Pendino, Mona Samy, Eric Nguyen, and Evelyne Ségal-Bendirdjian</td>
</tr>
<tr>
<td>720</td>
<td>Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications</td>
<td>Arun Bhardwaj, Seema Singh, Sanjeev K. Srivastava, Richard E. Honkanen, Eddie Reed, and Ajay P. Singh</td>
</tr>
<tr>
<td>732</td>
<td>CCN1, a Candidate Target for Zoledronic Acid Treatment in Breast Cancer</td>
<td>Ingrid Espinoza, Hong Liu, Robert Busby, and Ruth Lupu</td>
</tr>
<tr>
<td>742</td>
<td>A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers</td>
<td>Michael Faibish, Ralph Francescone, Brooke Bentley, Wei Yan, and Rong Shao</td>
</tr>
<tr>
<td>752</td>
<td>Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers</td>
<td>Xue Gong, Ruihong Wu, Hongwei Wang, Xinwu Guo, Dong Wang, Yunyan Gu, Yuannv Zhang, Wenyuan Zhao, Lixin Cheng, Chenguang Wang, and Zheng Guo</td>
</tr>
<tr>
<td>761</td>
<td>Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein-Mediated Drug Resistance</td>
<td>I-Ping Huang, Shu-Pin Sun, Shih-Hsun Cheng, Chia-Hung Lee, Chia-Yan Wu, Chung-Shi Yang, Leu-Wei Lo, and Yiu-Kay Lai</td>
</tr>
<tr>
<td>784</td>
<td>Determinants of Mitotic Catastrophe on Abrogation of the G2 DNA Damage Checkpoint by UCN-01</td>
<td>Kin Fan On, Yue Chen, Hoi Tang Ma, Jeremy P.H. Chow, and Randly Y.C. Poon</td>
</tr>
<tr>
<td>795</td>
<td>(--)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling–Mediated Angiogenesis</td>
<td>Xiueng Pang, Yuanyuan Wu, Yougen Wu, Binbin Lu, Jing Chen, Jieqiong Wang, Zhengfang Yi, Weijjing Qu, and Mingyao Liu</td>
</tr>
<tr>
<td>806</td>
<td>Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells</td>
<td>Deepak Raina, Michio Kosegi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimagura, Geoffrey I. Shapiro, Jeffrey Supko, Surender Kharbanda, and Donald Kufe</td>
</tr>
<tr>
<td>817</td>
<td>Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer</td>
<td>Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Sioum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura, and José Baselga</td>
</tr>
<tr>
<td>825</td>
<td>High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker α-Methylacyl Coenzyme A Racemase (AMACR/P504S)</td>
<td>Brice A.P. Wilson, Haofan Wang, Benjamin A. Nacev, Ronnie C. Mease, Jun O. Liu, Martin G. Pomper, and William B. Isaacs</td>
</tr>
</tbody>
</table>
## PRECLINICAL DEVELOPMENT

### 839
**Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol**  
Jenna L. Riffell, Reiner U. Jänicke, and Michel Roberge

### 850
**A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression**  
Franziska van Zijl, Sabine Mall, Georg Machat, Christine Pirker, Robert Zeillinger, Andreas Weinhaeusel, Martin Bilban, Walter Berger, and Wolfgang Mikulits

### 861
**Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family**  

### 874
**2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo**  
Thomas J.A. Snoeks, Isabel M. Mol, Ivo Que, Eric L. Kajzel, and Clemens W.G.M. Lowik

### 883
**Curcumin Inhibition of the Functional Interaction between Integrin α6β4 and the Epidermal Growth Factor Receptor**  
Young Hwa Soung and Jun Chung

### 892
**Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A**  

### 902
**Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment**  
Jianfeng Lu, Donna McEachern, Haiying Sun, Longchuan Bai, Yuefeng Peng, Su Qiu, Rebecca Miller, Jinhui Liao, Han Yi, Meilan Liu, Anita Bellail, Chunhai Hao, Shi-Yong Sun, Adrian T. Ting, and Shaomeng Wang

---

## ABOUT THE COVER

Migration of hepatocellular carcinoma (HCC) cells that have undergone epithelial to mesenchymal transition (EMT). The 3sp cells transdifferentiated from malignant hepatocytes in the HCC patient via EMT show a migratory potential as determined by Platypus technology that can be modulated by pharmacological interference. Migrating cells are visualized by staining with CellTracker. For details, see article by van Zijl and colleagues on page 850.
Molecular Cancer Therapeutics

10 (5)

Mol Cancer Ther 2011;10:709-914.

Updated version  Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/5.citation

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.